Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients. Traficet-EN is being developed under a strategic alliance with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 The nation,s newest ... a Las Vegas courtroom.  Attorneys representing ... the men suffered severe effects, including death, after using the ... clients what they as a company knew, that their drug ... Robert Eglet .  "In order to hold Takeda responsible ...
(Date:8/27/2015)... Itamar Medical Ltd. (TASE:ITMR) and ... public equity (PIPE) deal, in which Viola Private Equity ...   Through this deal, Viola Private Equity ... will work closely with the company,s management to accelerate ... investment agreement, Itamar Medical will issue shares to Viola ...
(Date:8/27/2015)... , Aug. 27, 2015  Zimmer Biomet Holdings, Inc. ... healthcare, announced that it will be participating in the ... the Goldman Sachs offices in London ... the Company Founded in 1927 and headquartered in ... global leader in musculoskeletal healthcare.  We design, manufacture and ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
... Ingelheim Pharmaceuticals, Inc. will present new phase Ib data ... annual meeting in Chicago (June 3-7) that indicates combining ... the maximum tested dose controlled disease in all (n=22) ... non-small cell lung cancer (NSCLC) who developed acquired resistance ...
... NEW YORK, May 25, 2011 ... research report is available in its ... Devices Market Outlook in Brazil to ... Infusion Systems, Central Venous Catheters and ...
Cached Medicine Technology:Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 2Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 3Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 4Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 5Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 6Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 7Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 2Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 3Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 4Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 5Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 6Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 7Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 8Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 9Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 10Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 11
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of ... the Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and ... State University study. , While most people don’t develop persistent depression after a ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... today that its Krames Patient Education content is ICD-10 ready and available to ... for the new ICD-10 code sets, which are more targeted and return a ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... In addition ... Alvernia University now offers a third doctoral program at its main campus in Reading: ... a terminal degree program designed to prepare advanced practice nurses for the highest level ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... partnership agreement for quality market research promotion on the Internet. MarketPublishers.com is ... Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager at ...
(Date:8/27/2015)... ... , ... Sunbelt® Bakery, maker of delicious granola snacks that have a bakery-fresh ... how protein bars should taste with the launch of its new line of protein ... market today. , The new Protein Delights are individually wrapped wafer bars that ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... Fight for Healthy BabiesLONG BEACH and FOUNTAIN VALLEY, Calif., ... of MemorialCare Medical Centers and one of the nation,s ... named Southern California chair for the 2009 March for ... Southern California for his special interest in improving the ...
... Month and Change the Lives of Children and ... the nation,s largest non-profit provider of autism services, ... family members and professionals should have access to ... necessary services, supports and guidance at every life ...
... HL7 interoperability for the Department of Defense,s MiCare System at the IHE ... ... iNTERFACEWARE is pleased to announce that its Iguana HL7 ... of MiCare at the HIMSS Convention in Chicago next week. , ...
... With the Easter holiday fast approaching, tons of chocolate will soon be ... dark and milk chocolate and which is healthier for you. , ... ... tons of chocolate Easter Bunnies are unleashed on the world; given as ...
... free quotes for guaranteed issue health insurance plans for individuals who ... a major medical policy. , ... Dallas, TX (PRWEB) ... the addition of a new health plan available to all individuals ...
... (April 1, 2009) It appears that a drug ... similar effect on the compulsive behavior of kleptomaniacs it ... the University of Minnesota., The Medical School,s Department of Psychiatry ... ages 17-75, who spent an average of at least one ...
Cached Medicine News:Health News:Barry Arbuckle, Ph.D., President & CEO of MemorialCare Medical Centers to Chair Southern California March for Babies 2009, March of Dimes Largest Fundraising Events 2Health News:The Time to Act for Families is Now - Will You Act for Autism With Easter Seals? 2Health News:The Time to Act for Families is Now - Will You Act for Autism With Easter Seals? 3Health News:The Time to Act for Families is Now - Will You Act for Autism With Easter Seals? 4Health News:Iguana Selected for Department of Defense IHE Demonstration at HIMSS 09 2Health News:Iguana Selected for Department of Defense IHE Demonstration at HIMSS 09 3Health News:Poison Dressed as an Easter Bunny 2Health News:Free Quotes for Health Insurance Anyone Can Qualify For 2Health News:Free Quotes for Health Insurance Anyone Can Qualify For 3
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... 3 system consists of the Model 7432 ... MemoryMod Software Cartridge. , ,Enterra™ Therapy ... nausea and vomiting associated with gastroparesis when ... relief of symptons for diabetic or idiopathic ...
... Intramuscular Lead is a unipolar lead intended for ... has a ski needle design for easier use ... a fixed electrode length of 1 cm. The ... is available in 35 cm length. Two leads ...
Medicine Products: